FIBROBIOLOGICS, LLC
Development of a Novel Therapeutic Agent for Skin Fibrosis
Development of a Novel Therapeutic Agent for Skin Fibrosis is a funding opportunity from FIBROBIOLOGICS, LLC, up to 306518, closing August 31, 2026.
Aug 31, 2026
(31d left)Overview
Systemic sclerosis or scleroderma is an autoimmune rheumatic disease characterized by fibrosis of the skin and internal organs that has the highest case fatality among rheumatic diseases. The increased deposition of collagen and other extracellular matrix proteins in the tissues leads to impaired function of visceral…